2 results
Approved WMOCompleted
The first objective is to evaluate the superiority of CHF 5259 pMDI (glycopyrrolate bromide) (50 µg total daily dose) versus placebo in terms of FEV1 AUC0-12h normalised by time on Day 42.Key Secondary objectiveTo evaluate the superiority of CHF…
Approved WMOCompleted
In a pilot study patients scheduled for a regular implantation of a (or undergoing an upgrade to a) CRT-device will also be implanted with a heart monitor in the pulmonary artery. This implantable heart monitor (IHM) will collect data during…